GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biolase Technology, Inc. (BIOL) [hlAlert]

Rating:
Outperform
BIOL
down 15.11 %

Biolase Technology, Inc. (BIOL) rated Outperform with price target $4 by Northland Securities

Posted on: Friday,  Sep 7, 2012  8:25 AM ET by Northland Securities

Northland Securities rated Outperform Biolase Technology, Inc. (NASDAQ: BIOL) on 09/07/2012, when the stock price was $1.72. Since
then, Biolase Technology, Inc. has lost 15.12% as of 10/06/2015's recent price of $1.46.
If you would have followed this Northland Securities's recommendation on BIOL, you would have lost 15.11% of your investment in 1124 days.

Biolase Technology, Inc. is a medical technology company that develops, manufactures and markets lasers, related products and services focused on technologies for applications and procedures in dentistry and medicine. The Company?s Waterlase Dentistry solution is a group of products, including dental laser systems that allow dentists, periodontists, endodontists, oral surgeons and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. Its systems are designed to provide many types of dental procedures. The Waterlase Dentistry solution offers two categories of laser system products: its Waterlase family of products and its Diode family of products, which includes the Company?s ezlase system, as well as related consumables, training and services.

Our equity research effort attempts to identify high potential small-cap investment ideas. We offer traditional sell-side research services with a particular focus on unearthing information that either supports or challenges our investment thesis. We strive to continuously provide our institutional client base with timely and insightful thinking.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/7/2012 8:25 AM Buy
None
1.72 4.00
as of 12/31/2012
1 Week   
1 Month up  6.28 %
3 Months up  9.41 %
1 YTD up  8.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy